Key Highlights

  • OKYO Pharma will take part in three ophthalmic conferences over the two weeks following September 29, 2026.
  • CEO Robert J. Dempsey presents at Eyecelerator in New Orleans on October 8, 2026, at 1:29 PM Central Time.
  • Other meetings are Optometry, September 30 to October 1, and the Academy of Ophthalmology, October 9 to 12.
  • OKYO plans a global Phase 3 urcosimod trial in about 111 patients with neuropathic corneal pain in late 2026.

OKYO Pharma Ltd (NASDAQ:OKYO) furnished a Form 6-K on September 29, 2026, attaching a press release that lays out its participation in three ophthalmic conferences over the following two weeks. The release describes the company as a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain, known as NCP, and for anterior segment eye diseases.

It also restates the company's plan for a global Phase 3 pivotal trial of its drug candidate urcosimod, to enroll approximately 111 patients.

The Three Conferences

The first event is the American Academy of Optometry meeting, which the release places in Anaheim from September 30 to October 1. For that conference and for the American Academy of Ophthalmology meeting, the release says OKYO's Leadership team will engage with experts in optometry and ophthalmology respectively. The American Academy of Ophthalmology meeting is listed for October 9 to 12 in New Orleans.

The centerpiece is Eyecelerator, scheduled for October 8, 2026, in New Orleans, Louisiana. OKYO's presentation is titled "Addressing Unmet Needs in Corneal and Anterior Segment Diseases." The release gives the time as Thursday at 1:29 PM Central Time, in a breakout session in Room 243-245. The presenter is Robert J. Dempsey, the company's Chief Executive Officer, and the session moderators are named as Julie Schallhorn, MD, MS, and Kendall Donaldson, MD.

The Planned Phase 3 Trial

The release states that OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026. The trial is described as enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP. Those are the only trial design details in the release.

Because the second half of 2026 runs through December 31, the release leaves open when within that period enrollment could begin.

What This Type of Filing Does and Does Not Show

A Form 6-K is the report used by foreign private issuers to furnish to the SEC information they have made public in their home market or otherwise distributed to shareholders. Here the exhibit is a notice of upcoming conference appearances. The filing is therefore best read as a schedule of where the company's executives will be, not as a development or results update.

The release closes with a contact for Business development and investor relations, Paul Spencer, with a London telephone number and a general company email address. It lists the company's Nasdaq symbol as OKYO.

OKYO's Phase 3 Start and Conference Follow-Through

The dates in the release are the ones to track. The American Academy of Optometry meeting runs September 30 to October 1, the Eyecelerator presentation takes place on October 8, and the American Academy of Ophthalmology meeting runs October 9 to 12. The other item to watch is the Phase 3 trial, which the company says it plans to start in the second half of 2026; the filing gives no interim milestone before that.